Comparative In Vitro Killing Activities of Meropenem, Imipenem, Ceftriaxone, and Ceftriaxone plus Vancomycin at Clinically Achievable Cerebrospinal Fluid Concentrations against Penicillin-Resistant Streptococcus pneumoniae Isolates from Children with Meningitis | Zendy

F. Fitoussi | Zendy; C. Doit | Zendy; Karim Bénali | Zendy; Stéphane Bonacorsi | Zendy; Pierre Geslin | Zendy; Édouard Bingen | Zendy

Open Access

Comparative In Vitro Killing Activities of Meropenem, Imipenem, Ceftriaxone, and Ceftriaxone plus Vancomycin at Clinically Achievable Cerebrospinal Fluid Concentrations against Penicillin-Resistant Streptococcus pneumoniae Isolates from Children with Meningitis

Author(s) -

F. Fitoussi,

C. Doit,

Karim Bénali,

Stéphane Bonacorsi,

Pierre Geslin,

Édouard Bingen

Publication year - 1998

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.42.4.942

Subject(s) - meropenem , ceftriaxone , imipenem , vancomycin , microbiology and biotechnology , penicillin , streptococcus pneumoniae , medicine , antibiotics , meningitis , antibacterial agent , biology , bacteria , antibiotic resistance , surgery , staphylococcus aureus , genetics

The activities of meropenem, imipenem, ceftriaxone, and vancomycin were evaluated against 80 penicillin-susceptible and -resistant Streptococcus pneumoniae strains. Meropenem, imipenem, ceftriaxone, and vancomycin MICs at which 90% of the isolates are inhibited were 0.5, 0.25, 1, and 0.25 microg/ml, respectively. Against penicillin-resistant strains, the best killing activity at cerebrospinal fluid concentrations was obtained with imipenem and ceftriaxone-vancomycin. However, while the killing activity of imipenem was significantly greater than that of meropenem, no significant difference was observed between the activities of meropenem and ceftriaxone-vancomycin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research